Advertisement

Reactions Weekly

, Volume 1710, Issue 1, pp 123–123 | Cite as

Docetaxel/ramucirumab

Various toxicities: 12 case reports
Case report
  • 6 Downloads

Reference

  1. Hata A, et al. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. Oncotarget 9: 27789-27796, No. 45, 12 Jun 2018. Available from: URL: http://doi.org/10.18632/oncotarget.25578- Japan

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations